Mersana Therapeutics (MRSN) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts MRSN Hot Sheet
Join SI Premium – FREE
Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $16.36 million versus the consensus estimate of $7.38 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- Jefferies sees metals breakout on currency concerns
- BofA maintains underperform ratings on six BDC stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
